Legacy Financial Advisors Inc. Takes Position in Sanofi $SNY

Key Points

• Legacy Financial Advisors Inc. has acquired a new position in Sanofi, purchasing 5,144 shares valued at approximately $285,000 in the first quarter.
• Sanofi's latest quarterly earnings report revealed an EPS of $0.90, which was below analyst expectations of $0.96, despite revenue exceeding forecasts at $11.34 billion.
• Analysts have shown optimistic views on Sanofi's stock, with recent upgrades leading to an average target price of $62.00 and multiple ratings of "Buy" or "Strong Buy."

Legacy Financial Advisors Inc. purchased a new position in shares of Sanofi (NASDAQ:SNY - Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 5,144 shares of the company's stock, valued at approximately $285,000.

Several other hedge funds have also made changes to their positions in SNY. Accent Capital Management LLC bought a new position in Sanofi during the 1st quarter worth $29,000. Eastern Bank boosted its holdings in shares of Sanofi by 121.0% during the first quarter. Eastern Bank now owns 548 shares of the company's stock valued at $30,000 after acquiring an additional 300 shares during the period. Golden State Wealth Management LLC grew its position in shares of Sanofi by 619.3% during the first quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock worth $35,000 after acquiring an additional 545 shares during the last quarter. Brentview Investment Management LLC acquired a new stake in shares of Sanofi in the 1st quarter worth about $42,000. Finally, UMB Bank n.a. lifted its position in Sanofi by 30.7% in the 1st quarter. UMB Bank n.a. now owns 1,124 shares of the company's stock valued at $62,000 after purchasing an additional 264 shares during the last quarter. Institutional investors own 14.04% of the company's stock.

Sanofi Stock Performance

Shares of NASDAQ SNY opened at $50.53 on Thursday. Sanofi has a 1 year low of $44.73 and a 1 year high of $60.12. The firm has a market cap of $124.08 billion, a P/E ratio of 12.15, a PEG ratio of 1.20 and a beta of 0.48. The stock has a fifty day moving average price of $48.59 and a two-hundred day moving average price of $51.76. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). The firm had revenue of $11.34 billion during the quarter, compared to the consensus estimate of $9.91 billion. Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The firm's quarterly revenue was down 7.0% on a year-over-year basis. During the same period in the prior year, the firm posted $1.73 EPS. Research analysts forecast that Sanofi will post 4.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

SNY has been the subject of several recent analyst reports. Hsbc Global Res upgraded shares of Sanofi to a "strong-buy" rating in a research report on Monday, April 28th. Morgan Stanley set a $56.00 price objective on Sanofi in a research report on Monday, June 2nd. Barclays restated an "overweight" rating on shares of Sanofi in a research report on Wednesday, July 2nd. Wall Street Zen raised Sanofi from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Finally, Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Sanofi in a research report on Tuesday, August 5th. Three research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, Sanofi currently has an average rating of "Buy" and an average target price of $62.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.